Literature DB >> 21703444

Stuck in the middle: drugging the ubiquitin system at the e2 step.

J Wade Harper1, Randall W King.   

Abstract

The discovery of a small-molecule allosteric inhibitor of the CDC34 ubiquitin-conjugating enzyme (E2) by Ceccarelli et al. raises the possibility that it will be generally feasible to selectively inhibit ubiquitin transfer at this central step in the ubiquitin pathway.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID： 21703444     DOI： 10.1016/j.cell.2011.06.002

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  5 in total

Review 1.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

Review 2.  Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system.

Authors:  Dennis L Buckley; Craig M Crews
Journal:  Angew Chem Int Ed Engl       Date:  2014-01-23       Impact factor: 16.823

Review 3.  New Insights into the Role of E2s in the Pathogenesis of Diseases: Lessons Learned from UBE2O.

Authors:  Daniel Hormaechea-Agulla; Youngjo Kim; Min Sup Song; Su Jung Song
Journal:  Mol Cells       Date:  2018-03-20       Impact factor: 5.034

Review 4.  UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy.

Authors:  Ivan Presta; Fabiana Novellino; Annalidia Donato; Domenico La Torre; Caterina Palleria; Emilio Russo; Natalia Malara; Giuseppe Donato
Journal:  Int J Mol Sci       Date:  2020-03-17       Impact factor: 5.923

Review 5.  Development of inhibitors in the ubiquitination cascade.

Authors:  Wei Zhang; Sachdev S Sidhu
Journal:  FEBS Lett       Date:  2013-11-12       Impact factor: 4.124
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.